Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383
Debt
Debt-to-Equity Ratio0.62
Current Ratio8.89
Quick Ratio8.89
Price-To-Earnings
Trailing P/E Ratio-1.30
Forward P/E Ratio-1.61
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book1.54
Profitability
EPS (Most Recent Fiscal Year)($1.05)
Net Income$-20,980,000.00
Net MarginsN/A
Return on Equity-87.38%
Return on Assets-58.99%
Miscellaneous
Employees14
Outstanding Shares21,260,000
Market Cap$32.53 million
Lipocine (NASDAQ:LPCN) Frequently Asked Questions
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine Inc (NASDAQ:LPCN) posted its earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.10. View Lipocine's Earnings History.
When is Lipocine's next earnings date?
What price target have analysts set for LPCN?
4 equities research analysts have issued 12-month price targets for Lipocine's shares. Their forecasts range from $1.50 to $11.00. On average, they anticipate Lipocine's stock price to reach $6.3750 in the next twelve months. This suggests a possible upside of 365.3% from the stock's current price. View Analyst Price Targets for Lipocine.
What is the consensus analysts' recommendation for Lipocine?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lipocine.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include Juniper Pharmaceuticals (JNP), Intec Pharma (NTEC), Steadymed (STDY), Trevena (TRVN), Sol Gel Technologies (SLGL), VBI Vaccines (VBIV), Iterum Therapeutics (ITRM), Conatus Pharmaceuticals (CNAT), Recro Pharma (REPH), Catalyst Biosciences (CBIO), MOTIF BIO PLC/S (MTFB), Infinity Pharmaceuticals (INFI), Checkpoint Therapeutics (CKPT), Provention Bio (PRVB) and Zynerba Pharmaceuticals (ZYNE).
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 61)
- Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 50)
- Logan Morse, VP of Sales, Marketing & Operations (Age 48)
- Mr. Gregory B. Bass, Exec. VP & Chief Commercial Officer (Age 44)
- Nachiappan Chidambaram, VP of Product Devel. (Age 49)
Has Lipocine been receiving favorable news coverage?
News coverage about LPCN stock has been trending somewhat positive on Saturday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lipocine earned a coverage optimism score of 0.17 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 46.83 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Lipocine.
Who are Lipocine's major shareholders?
Lipocine's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.41%). Company insiders that own Lipocine stock include Gregory Brooks Bass, Jeffrey Arvin Fink, Mahesh V Patel, Morgan R Brown and Stephen A Hill. View Institutional Ownership Trends for Lipocine.
Which institutional investors are selling Lipocine stock?
LPCN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have sold Lipocine company stock in the last year include Gregory Brooks Bass, Jeffrey Arvin Fink, Mahesh V Patel, Morgan R Brown and Stephen A Hill. View Insider Buying and Selling for Lipocine.
How do I buy shares of Lipocine?
Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
One share of LPCN stock can currently be purchased for approximately $1.37.
How big of a company is Lipocine?
Lipocine has a market capitalization of $32.53 million. The specialty pharmaceutical company earns $-20,980,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Lipocine employs 14 workers across the globe.
How can I contact Lipocine?
Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]
MarketBeat Community Rating for Lipocine (NASDAQ LPCN)
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
